Shots:
- The NMPA has granted approval to Vyloy + fluoropyrimidine & Pt-based CT as a 1L treatment of locally advanced unresectable or metastatic HER2-, CLDN18.2+ G/GEJ adenocarcinoma
- Approval was supported by P-III (GLOW: n=145 & SPOTLIGHT: n=36) studies assessing Vyloy + CAPOX & mFOLFOX6, respectively, vs PBO among Chinese patients with this indication
- Studies depicted significantly improved PFS & OS, with mPFS of 8.21 vs 6.80mos. (GLOW) & 10.61 vs 8.67mos. (SPOTLIGHT) as well as mOS of 14.39 vs 12.16mos. (GLOW) & 18.23 vs 15.54mos. (SPOTLIGHT)
Ref: Astellas | Image: Astellas
Related News:- Astellas Reports the US FDA’s Approval of Vyloy (Zolbetuximab-clzb) to Treat Advanced G/GEJ Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
